Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer

PURPOSE: This randomized phase III study was designed to compare the efficacy and safety of irinotecan plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC). MATERIALS AND METHODS: Patients were randomly assigned to receive IP,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dong-Wan, Kim, Hoon-Gu, Kim, Joo-Hang, Park, Keunchil, Kim, Hoon-Kyo, Jang, Joung Soon, Kim, Bong-Seog, Kang, Jin-Hyoung, Lee, Kyung Hee, Kim, Sang-We, Ryoo, Hun Mo, Kim, Jin-Soo, Lee, Ki Hyeong, Kwon, Jung Hye, Choi, Jin-Hyuk, Shin, Sang Won, Hahn, Seokyung, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334001/
https://www.ncbi.nlm.nih.gov/pubmed/29529858
http://dx.doi.org/10.4143/crt.2018.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334001/
https://www.ncbi.nlm.nih.gov/pubmed/29529858
http://dx.doi.org/10.4143/crt.2018.019

Ejemplares similares